kras g-12c inhibitor 19

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

C-Met inhibitor D9 is a c-Met kinase inhibitor.

PKM2 inhibitor G is a inhibitor of pyruvate kinase.

ACHE Inhibitor 12 inhibited acetylcholinesterase with an IC50 value of 0.38 µM.

GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.GSK-3β inhibitor 12 can be used for the study of Parkinson's in the presence of lipopolysaccharide induction.

Protein Kinase C 19-31 acetate, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate

MMP-12 Inhibitor is a selective inhibitor of MMP-12 with IC50s of 2, 160, 320, and 22.3 nM for human, mouse, rat, and sheep MMP-12.

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

C-Myc Inhibitor 7, serving as both a c-Myc inhibitor and a multi-target protein degrader, effectively degrades proteins c-MYC, CK1α, GSPT1, and IKZF1/2/3 across various tumor cell types. It holds potential for research into diseases associated with high c-Myc expression, including cancer, cardiovascular and cerebrovascular conditions, and viral infections.

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

VPS34 inhibitor 1 (Compound 19, PIK-III analogue) (PIK-III analogue) is a potent and selective inhibitor of VPS34( IC50 : 15 nM)

Protein kinase G inhibitor-2 exhibits antibacterial, antiviral, and antitumor activities.

KRAS inhibitor-9 (DUN09716) is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSC-LC cells with KRAS mutation but not normal lung cells

K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of the oncogenic K-Ras(G12C) protein.

KRAS inhibitor-11 is a KRAS inhibitor .

ATX inhibitor 19 is a potent inhibitor of ATX (IC50: 156 nM).

KRAS G12C inhibitor 43 is a potent inhibitor of KRAS G12C and inhibits the migration and proliferation of H358 cells (IC50: 0.001-1 μM μM), A549 cells (IC50>1 μM) and HCC cells (IC50>1 μM).

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.

ATX inhibitor 12 is an orally active ATX inhibitor (IC50: 1.72 nM). In C57Bl/6J mice, oral administration of ATX inhibitor 12 at a dose of 60 mg/kg was effective in inhibiting structural lung damage and reducing fibrotic lesions.

KRAS G12C inhibitor 22 is a specific inhibitor of the KRAS G12C mutation.

Bromodomain Inhibitor-12 Edisylate (example 303) serves as a bromodomain inhibitor applicable to autoimmune and inflammatory disease research [1].

mTOR inhibitor-12 (Compound 11), a selective, brain-penetrant mTOR inhibitor, exhibits no genotoxicity risk and is utilized in research pertaining to central nervous system (CNS) diseases [1].

c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM, demonstrating cytotoxic effects on various cancer cell lines, including A549, HT-29, SGC-7901, and MDA-MB-231, with IC50 values of 0.25, 0.36, 0.98, and 0.76 μM, respectively [1].

KRAS inhibitor-14 is a potent inhibitor of KRAS G12C (IC50: 0.249 μM). KRAS inhibitor-14 exhibited p-ERK inhibition in MIA PaCA-2, A549 cells with IC50s of 1.12, >33.3 μM, respectively. KRAS inhibitor-14 has potential to be investigated in pancreatic, colorectal and lung cancers.

BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC 50 = 2.7 nM).

KRAS G12C Inhibitor 37, a potent inhibitor of KRAS G12C, targets the Ras family of proteins, crucial for intracellular signaling related to growth and development. This compound holds potential for research into cancers mediated by KRAS G12C.

KRAS G12C inhibitor 20 is an inhibitor specifically targeting the KRAS G12C mutation.

PI3K mTOR Inhibitor-12, a potent and selective orally active inhibitor, exhibits IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR, indicating significant antitumor activity with reduced liver toxicity [1].

KRAS G12D Inhibitor 10 is a potent agent targeting the KRAS G12D mutation, a variant in the Ras protein family crucial for cellular growth and development. This compound shows promise for investigating cancers mediated by KRAS G12D.

C-Myc Inhibitor 8 is an effective compound for cancer research, inhibiting cell viability across a range of cancer types and demonstrating growth suppression in human prostate and lung cancers within mouse models. This inhibitor specifically targets the c-Myc pathway, showcasing its potential utility in oncological studies.

KRAS inhibitor-3, an efficacious inhibitor of both wild-type (WT) and oncogenic KRAS mutations, exhibits high-affinity binding (K D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, and 0.74 μM for KRAS Q61H). Additionally, it impedes the interaction between KRAS and Raf, highlighting its potential as a targeted therapeutic agent in KRAS-mutant cancers.

Protein Kinase C (19-35) Peptide, acting as a PKC pseudosubstrate inhibitor region, can potentially inhibit PKC activity by blocking the substrate-binding site within the kinase domain, thereby inactivating the cytoplasmic form of PKC [1] [2].

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

Protein Kinase C (19-36) is a pseudosubstrate peptide that inhibits protein kinase C (PKC) with an IC50 of 0.18 μM.

CypD inhibitor C-9 is a CypD inhibitor, it attenuates mitochondrial and cellular perturbation insulted by Aß and calcium stress.

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.

Tuberculosis Inhibitor 12, an oxadiazole derivative, effectively inhibits Mycobacterium tuberculosis, demonstrating inhibition rates of 82% and 78% at a concentration of 20 μM on 7H9-Tw-OADC media, respectively [1].

19-O-beta-D-carboxyglucopyranosyl-12-O-beta-D-glucopyranosyl-11,16-dihydroxyabieta-8,11,13-triene is a natural product of Pinus, Pinaceae. The catalog number is TN6493 and the CAS number is 1011714-20-7. 19-O-beta-D-carboxyglucopyranosyl-12-O-beta-D-glucopyranosyl-11,16-dihydroxyabieta-8,11,13-triene can be used as a reference standard.

KRAS inhibitor-4 developed as anticancer agents, is a potent KRAS inhibitor.

KRAS G12C inhibitor 21 is a specific inhibitor targeting the KRAS G12C mutation.

c-Myc inhibitor 4 is a potent, orally active compound that reduces c-Myc, an important proto-oncogene closely associated with the development of many tumors.

KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.

c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to further enhance kinase selectivity. c-Met-IN-12 exhibits anti-tumour activity.

KRAS G12D inhibitor 9 is a potent agent targeting KRAS G12D, an important member of the RAS protein family involved in intracellular signaling crucial for growth and development. This inhibitor shows significant research potential for KRAS G12D-mediated cancer.

KRAS inhibitor-12 (compound 6-1) is a potent inhibitor of KRAS G12C (IC50: 0.537 μM), exhibiting p-ERK inhibition in MIA PaCA-2 and A549 cells with IC50 values of 1.3 and 3.7 μM, respectively. KRAS inhibitor-12 has potential for study in pancreatic, colorectal, and lung cancers.

KRAS inhibitor-8 is a potent inhibitor of the mutated KRAS G12C protein.

KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor [for potential treatment in cancer].